Clinical trial
THE CAPITAL PCI AF Study: The Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
NCT03331484 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- THE CAPITAL PCI AF Study: The Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 1, 2018
- Completion date
- July 6, 2023
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.